Sonoma Pharmaceuticals, Inc. (SNOA)
Market Cap | 5.16M |
Revenue (ttm) | 12.51M |
Net Income (ttm) | -5.79M |
Shares Out | 3.11M |
EPS (ttm) | -2.00 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 64,742 |
Open | 1.61 |
Previous Close | 1.64 |
Day's Range | 1.60 - 1.67 |
52-Week Range | 1.00 - 4.25 |
Beta | 1.04 |
Analysts | Buy |
Price Target | n/a |
Earnings Date | Feb 9, 2023 |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing throug... [Read more]
Full Company ProfileFinancial Performance
In 2022, SNOA's revenue was $12.63 million, a decrease of -32.21% compared to the previous year's $18.63 million. Losses were -$5.09 million, 28.8% more than in 2021.
Financial StatementsNews

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
BOULDER, CO / ACCESSWIRE / January 31, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorou...

Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?
Sonoma Pharmaceuticals (NASDAQ: SNOA) stock is rocketing higher on Wednesday following positive news for its Microcyn Rx products. The big news here is Sonoma Pharmaceuticals getting a Distribution a...

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
BOULDER, CO / ACCESSWIRE / January 25, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorou...

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
BOULDER, CO / ACCESSWIRE / January 4, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results
International sales increased by 18% in the six months ended September 30, 2022 compared to the same period prior year Gross profit percentage continues to trend upwards with the quarter ended Septemb...

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States
BOULDER, CO / ACCESSWIRE / October 27, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorou...

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany
BOULDER, CO / ACCESSWIRE / October 6, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide ran...

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results
Revenue increase of 73% from Q4 22 and 8% from Q1 22 Reduction of net loss by $0.2 million or 19% versus Q1 22 Reduction of EBITDAS loss by $0.2 million or 23% versus Q1 22 Reduction in net loss per s...

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply
WOODSTOCK, GA / ACCESSWIRE / August 2, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorou...

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results
Revenues increased 7% in Q4 2022 compared to Q4 2021 Net loss per share improved quarter over quarter and year over year Strong balance sheet with $7.4 million of cash WOODSTOCK, GA / ACCESSWIRE / Jul...

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl...

Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?
Sonoma Pharmaceuticals (SNOA) stock is getting a boost on Tuesday after the company revealed positive disinfectant news from the EPA. The post Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl...

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, G...

Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa. Microdox is a super-oxidized solutio...

Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl...

Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli...

Sonoma Pharma Expands Its Partner Network For Oral, Dental Products In US & China
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has added Salus Medical as an additional distribution partner in the U.S for dental care. The Company has also expanded its oral and dental care lines to Chin...

Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl...

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli...

Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli...

Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli...

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli...

Why SNOA Stock Is Getting a Bezos-Sized Boost Today
Today, investors in Sonoma Pharmaceuticals and SNOA stock are seeing impressive gains as the company launches its products on Amazon. The post Why SNOA Stock Is Getting a Bezos-Sized Boost Today appea...